Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics gets European patent for Microcrystalline Tyrosine technology

Similar patents have already been granted in the UK and in New Zealand
a mosquito biting the flesh of a human
When coupled with another adjuvant, MCT has shown positive efficacy in a malaria model

Allergy Therapeutics plc (LON:AGY) has strengthened its core intellectual property after the European Patent Office granted it a broad technology patent for its Microcrystalline Tyrosine (MCT) depot adjuvant manufacturing process.

The patent covers the novel manufacture and physiochemical characteristics of MTC in combination with one or more antigens, Allergy said.

The company had already been granted similar patents in the UK and in New Zealand for the MCT technology.

“We are pleased to expand this key patent and are excited by the potential for MCT as a core technology within our adjuvant portfolio to create novel and efficacious vaccines,” said chief executive Manuel Llobet.

“This further underpins the future pipeline for products, and the long term success of Allergy Therapeutics to continue innovating and producing novel medicines.”

An adjuvant is a substance which enhances the body’s immune response to an antigen. In the case of MCT, it extends the time available for the immune system to process an antigen.

Recent data has shown that MCT has a synergistic effect when coupled with another adjuvant, Virus Like Particles.

This combined adjuvant system demonstrated positive efficacy in a malaria model in a study performed in collaboration with the University of Oxford.

Shares were up 5% in early deals on Wednesday.

View full AGY profile View Profile

Allergy Therapeutics PLC Timeline

Related Articles

September 25 2018
A decision on whether or not Motif can start marketing its next-generation antibiotic in the US is due by mid-February
test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
scientist with vial
September 25 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use